Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
复制标题
DOI：
10.1002/ajh.20381
复制
发表时间：
2005-08-01
影响因子：
12.8
通讯作者：
Grateau, G
中科院分区：
文献类型：
--
作者：
Gertz, MA;Comenzo, R;Grateau, G
我们进行这项研究，以制定统一接受的标准，用于定义免疫球蛋白轻链淀粉样变性（AL）治疗方案中患者的器官受累和反应。召集了一个由13名积极参与淀粉样变性患者治疗的专家组成的共识小组。每个机构都提交了机构标准，并达成了共识，确定了每个有关机构和反应标准。根据2004年4月在法国图尔斯举行的第10届淀粉样蛋白和淀粉样变性国际研讨会的讨论结果，制定了具体标准，并商定了器官和血液学反应的定义。这些标准现在构成了参与和反应的工作定义，供今后收集和报告数据之用。我们报告的标准，中心现在可以用来定义器官参与和统一的反应标准，报告轻链AL患者的结果。
We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light-chain amyloidosis (AL). A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis. Institutional criteria were submitted from each, and a consensus was developed defining each organ involved and the criteria for response. Specific criteria have been developed with agreed on definitions of organ and hematologic response as a result of discussions at the 10(th) International Symposium on Amyloid and Amyloidosis held in Tours, France, April 2004. These criteria now form the working definition of involvement and response for the purposes of future data collection and reporting. We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL.